Recent Updates
Recently added Catalysts
ONC

Financial Information On

Key Takeaway: Financial Information On April 28, 2022, BeiGene, Ltd. (the "Company") filed its 2021 Annual Report for the year ended December 31, 2021 (the "STAR Annual Report") with the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange, which was prep

Full Press Release Details

Financial Information
On April 28, 2022, BeiGene, Ltd. (the "Company") filed its 2021 Annual Report for the year ended December 31, 2021 (the "STAR Annual Report") with the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples' Republic of China (the "PRC" and the "PRC Securities Laws"). The STAR Annual Report is available to the public in Chinese language only on the website maintained by the Shanghai Stock Exchange at www.sse.com.cn.
As required by the PRC Securities Laws, the STAR Annual Report contains additional financial information regarding the Company's gross profit margin ratio, research and development expenses allocated by key products and other research and development projects, and production, sales and inventory stock units of key products, for the year ended December 31, 2021 (the "Reporting Period"), prepared in accordance with the China Accounting Standards for Business Enterprises - Basic Standard ("CAS") and other applicable PRC accounting rules, guidance and interpretations (together with CAS, "PRC GAAP"). The key differences between such financial information prepared in accordance with PRC GAAP and those prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for the Reporting Period, which was previously filed with the U.S. Securities and Exchange Commission, are summarized below.
Key Differences between PRC GAAP and U.S. GAAP
Share-based Compensation
Under U.S. GAAP, the Company elects to recognize share-based compensation expenses using the straight-line method for all employee equity awards granted with graded vesting based on service conditions, provided that the amount of compensation cost recognized at any date is at least equal to the portion of the grant-date value of the options that are vested as of that date.
Under PRC GAAP, the Company recognizes share-based compensation expense using the accelerated method for all employee equity awards granted with graded vesting.
Excess tax income from the exercise of stock option
Under U.S. GAAP, deferred taxes are calculated based on the cumulative share-based compensation expense recognized in the financial statements and ASC 2016-09 requires all excess tax benefits and tax deficiencies to be recorded as income tax expense or benefit in the statement of operations, rather than in shareholders' equity.
Under PRC GAAP, deferred taxes are calculated based on the estimated tax deduction determined at each reporting date. If the tax deduction exceeds cumulative compensation cost for an individual award, tax benefits on the excess are credited to shareholders' equity. If the tax deduction is less than or equal to cumulative compensation cost for an individual award, tax expenses are recorded in the statement of operations.
Under U.S. GAAP, as a lessee, the Company recognizes a lease liability based on the present value of the total remaining lease payments, and a corresponding right-of-use assets under U.S. GAAP. The Company subsequently recognizes operating lease expenses on a straight-line basis over the lease term.
PRC GAAP requires entities to present interest expenses on the lease liability and depreciation on the right-of-use assets separately in the statements of operations. The combination of a straight-line depreciation of the right-of-use assets and the effective interest rate method applied to the lease liability will result in a higher total charge to profit or loss in the initial years of the leases and decreasing expenses during the latter part of the lease term.
Gross Profit Margin Ratio
As required by the PRC Securities Laws, the STAR Annual Report contains financial information regarding gross profit margin ratio by region, which was prepared in accordance with PRC GAAP. The corresponding financial information prepared in accordance with U.S. GAAP is presented below. Amounts reported herein are stated in thousands of U.S. dollars.
For the year ended December 31, 2021 For the year ended December 31, 2020
By Region Revenue COGS Gross Margin ratio Revenue COGS Gross Margin ratio
China 517,173 162,976 68.5% 290,646 70,388 75.8%
Ex-China 659,110 1,930 99.7% 18,228 269 98.5%
Total 1,176,283 164,906 308,874 70,657
Research and Development Expenses Allocated by Key Products and Other R D Projects
As required by the PRC Securities Laws, the STAR Annual Report contains financial information regarding research and development ("R D") expenses allocated by key products, which was prepared in accordance with PRC GAAP. The corresponding financial information prepared in accordance with U.S. GAAP is presented below. Amounts reported herein are stated in thousands of U.S. dollars.
Pipeline Products Projects Year ended December 31, 2021 Year ended December 31, 2020 Implementation
Zanubrutinib 141,495 154,806 Clinical stage
Tislelizumab 163,986 215,808 Clinical stage
Pamiparib 14,419 28,156 Clinical stage
Ociperlimab (BGB-A1217) 65,102 22,133 Clinical stage
Bcl-2 (BGB-11417) 10,978 4,950 Clinical stage
OX40 (BGB-A445) 2,225 3,010 Clinical stage
Other R D projects 79,556 73,536 Clinical preclinical stage
R D collaboration projects 198,964 226,505 N A
Subtotal of external R D expenses 676,725 728,904
Subtotal of internal R D expenses 782,514 565,973
Total 1,459,239 1,294,877
Production, Sales and Inventory Stock Units of Key Products
As required by the PRC Securities Laws, the STAR Annual Report contains financial information regarding the production, sales and inventory stock units of key products, which was prepared in accordance with PRC GAAP. The corresponding financial information prepared in accordance with U.S. GAAP is presented below.
Item Unit Production or purchase quantity for the year ended December 31, 2021 Sales quantity for the year ended December 31, 2021 Stock quantity as of December 31, 2021
Key products vials 1,984,300 1,119,800 932,900
Last updated: Apr 28, 2022